Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder
Authors:
- 1 September 1996
- journal article
- clinical trial
- Published by Wiley in Liver Transplantation and Surgery
- Vol. 2 (5) , 375-382
Abstract
Epstein‐Barr virus (EBV)‐induced posttransplant lymphoproliferative disorder (PTLD) develops in 3% to 10% of solid organ transplant recipients with a resultant mortality of up to 70%. Unfortunately, there is no current marker which identifies patients who will develop this disease. We therefore conducted a risk factor analysis of variables that might predict the development of PTLD. Specifically, since EBV may cause both PTLD and the development of monoclonal proteins (M protein), we sought to determine if the development of an M protein preceded and therefore might serve as a predictive marker of subsequent PTLD. Before and after liver transplantation, 201 patients were evaluated for the presence of urine and serum M proteins. Patients were followed to monitor the development of PTLD for a mean of 1,733 days. PTLD developed in seven patients (3.5%), three (43%) of whom died from disseminated PTLD. PTLD was classified as polymorphous in six patients and monomorphous in one patient. Fiftyseven patients (28%) developed an M protein after transplantation: five of seven patients (71%) with PTLD and 52/194 (27%) of patients without PTLD. Multivariate risk factor analysis for the development of an M protein after transplantation identified cytomegalovirus (CMV) donor seropositivity (P = 0.0002) and postoperative symptomatic CMV infection (P = 0.019) as risk factors. Whereas EBV serostatus of either the donor or recipient was not found to be a risk factor for the occurrence of either an M protein or PTLD, the development of a serum immunoglobulin M (IgM) M protein (P = 0.04) and of any urine M protein (P = 0.01) was identified by univariate analysis as being associated with the development of PTLD. Further studies are needed to determine the predictive value of M proteins as a marker for PTLD. Until such time, the development of serum or urine M protein should heighten the suspicion of developing PTLD. Copyright © 1996 by the American Association for the Study of Liver Diseases.Keywords
This publication has 31 references indexed in Scilit:
- PATTERNS OF EPSTEIN-BARR VIRUS LATENT AND REPLICATIVE GENE EXPRESSION IN EPSTEIN-BARR VIRUS B CELL LYMPHOPROLIFERATIVE DISORDERS AFTER ORGAN TRANSPLANTATIONTransplantation, 1994
- MONOCLONAL AND OLIGOCLONAL GAMMOPATHIES IN LIVER TRANSPLANT RECIPIENTSTransplantation, 1994
- Clinical Approach to Infection in the Compromised Host1994
- Epstein-Barr Virus Infections: Biology, Pathogenesis, and ManagementAnnals of Internal Medicine, 1993
- “Benign” Monoclonal Gammopathy—After 20 to 35 Years of Follow-UpMayo Clinic Proceedings, 1993
- Expression of Epstein–Barr Virus–Encoded Small RNA (by the EBER-1 Gene) in Liver Specimens from Transplant Recipients with Post-Transplantation Lymphoproliferative DiseaseNew England Journal of Medicine, 1992
- Quantitative Oropharyngeal Epstein-Barr Virus Shedding in Renal and Cardiac Transplant Recipients: Relationship to Immunosuppressive Therapy, Serologic Responses, and the Risk of Posttransplant Lymphoproliferative DisorderThe Journal of Infectious Diseases, 1992
- Increased Incidence of Lymphoproliferative Disorder after Immunosuppression with the Monoclonal Antibody OKT3 in Cardiac-Transplant RecipientsNew England Journal of Medicine, 1990
- HIGH INCIDENCE OF MONOCLONAL IMMUNOGLOBULINS IN PATIENTS AFTER LIVER OR HEART TRANSPLANTATIONTransplantation, 1988
- Epstein-Barr virus serologic testingThe Pediatric Infectious Disease Journal, 1986